权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanisms of immune control of intratumor heterogeneity and clonal competition

肿瘤内异质性和克隆竞争的免疫控制机制

基本信息

批准号：
10431216
负责人：
Flaminia Talos
金额：
$ 21.74万
依托单位：
STATE UNIVERSITY NEW YORK STONY BROOK
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-02-01 至 2024-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10431216
关键词：
Address Automobile Driving Biological Assay Cells Chemotaxis Clinical Clonal Evolution Clonal Expansion Clone Cells Communities Complex Coupled Disease Disease Outcome Disease Resistance Drug resistance Ecology Ecosystem Equilibrium Evolution Exhibits Exploratory/Developmental Grant Future Genetic Determinism Genomics Geography Goals Growth Human Immune Immune system In Vitro Interferon Type II Interferons Intervention MHC Class II Genes Malignant Neoplasms Malignant neoplasm of prostate Maps Minor Modeling Molecular Molecular Profiling Mutation Organoids Outcome Phenotype Population Role Shapes Solid Source Time Treatment Failure Tumor-infiltrating immune cells advanced disease anticancer research cancer therapy chemokine design fitness immunogenic immunological intervention immunoregulation improved in vivo innovation insight member mouse model multiple omics new therapeutic target non-genetic novel pre-clinical prevent prostate cancer model transcriptomics translational approach treatment strategy tumor tumor heterogeneity tumor microenvironment tumor-immune system interactions

项目摘要

PROJECT SUMMARY/ABSTRACT Intratumor heterogeneity (ITH) and clonal evolution pose tremendous challenges in designing effective and durable cancer therapies. This is highly relevant for PCa, a prime example of a highly heterogenous disease where fluctuating cellular subpopulations (“clones”) with distinct mutational and phenotypic profiles can coexist and evolve independently, diversify and compete during the course of the disease. The majority of ITH studies centers on genetic determinants, while non-genetic variability such as due to spatial clonal distributions and interactions of tumor subpopulations with each other and with the immune TME remain poorly understood. These mechanisms are multifaceted, context-dependent and difficult to investigate experimentally in vivo. However, these complex interactions might hold powerful anti-tumor interventions. For instance, mechanisms of elimination of “loser” cells/clones could be exploited to lower overall tumor fitness and new targeted therapies could be developed to counteract the factors that enable clonal dominance. We recently generated new reductionist models of ITH that reflect, at least in part, the clonal fitness diversity of human PCa. By incorporating multicolor lineage tracing in mouse models, longitudinal organoid studies and single cell transcriptomics, we showed that less severe models accommodate the coexistence of multiple growing tumor subpopulations. In contrast, aggressive tumors exhibit a drastic and rapid clonal reduction, emergence of larger dominant populations as slower-growing populations are out-competed by fast-growing ones in vivo and in vitro, and massive TME remodeling. In the same time, some minor populations persist and might serve as a reservoir for drug-resistant clones. Moreover, the minor populations have distinct immunoediting molecular signatures marked by increased expression of Cxcl9/Cxcl11 and MHC class II members. We hypothesize that direct competition mechanisms between dominant and minor clones within specialized TME niches coupled with fitness effects of the immune system on clonal expansions determine the ITH in PCa. The goal of this proposal is to identify molecular mechanisms and cellular contexts underlying clonal interactions with each other and with TME by pursuing 1) Functional mapping of tumor competitive landscapes in mouse models of PCa by spatial transcriptomic analyses and 2) Elucidate the role of Cxcl9/11 in reducing the fitness potential of minor clones by novel competition-chemotaxis and T-cell infiltration organoid assays and in vivo immunomodulatory interventions. Results from these studies will not only greatly expand our understanding of population-level interactions in tumors, but also uncover new targetable immunoediting mechanisms that operate at clonal level in driving clonal diversification and selection with impact on preventing progression to advanced disease and drug resistance.

项目总结/文摘